Grace Therapeutics, INC 10-Q quarterly reports

Grace Therapeutics Inc. reported its Q2 2026 financial results, highlighting a net loss of $15.79 million and a significant impairment charge, while continuing efforts to address FDA feedback on its lead drug candidate, GTx-104.

Grace Therapeutics reports significant progress for its lead drug candidate GTx-104 with FDA NDA acceptance and a PDUFA target date set for April 23, 2026, alongside reduced net losses.

Grace Therapeutics, Inc. filed an amended quarterly report (10-Q/A) to correct the reported number of outstanding common shares as of November 13, 2025.

Grace Therapeutics reported reduced net losses and cash burn, with its lead drug candidate GTx-104 progressing towards FDA approval with a PDUFA date set for April 23, 2026.

Grace Therapeutics, Inc. reported submitting its New Drug Application for lead candidate GTx-104 to the FDA, following positive Phase 3 trial results for aneurysmal subarachnoid hemorrhage.

Grace Therapeutics files an amendment to its Form 10-Q to correct the number of outstanding shares of common stock as of December 31, 2024.

Grace Therapeutics announces positive Phase 3 results for GTx-104 and provides an update on its financial condition for the quarter ended December 31, 2024.

Grace Therapeutics has completed enrollment in its Phase 3 trial for GTx-104 and reported a net loss of $3.4 million for the quarter ended September 30, 2024.

Acasti Pharma's Q1 2025 report shows a reduced net loss compared to the same period last year, driven by lower restructuring costs and a change in the fair value of warrant liabilities, while the company continues to advance its lead drug candidate, GTX-104.

Acasti Pharma's Q3 2024 report highlights a strategic shift towards its lead drug candidate, GTX-104, and a reduction in operating expenses.